Transition Therapeutics Inc. Announces 12-Week Data from HCV-I.E.T.
Phase I/II Clinical Trial Announces 12-week data from an open label, multi-centre
Phase I/II clinical trial evaluating the interferon enhancing product, HCV-I.E.T.,
in hepatitis C non-responders.
Beliefs about Disease Severity and Lifestyle Changes among Patients
with Chronic Hepatitis C
Major step in fight on hepatitis C
VIHA targets $1.5 million to halve HIV/AIDS, Hep C
High Body Mass Index and Hepatitis C Are Risk Factors for Posttransplant
Diabetes: Presented at WTC
Ontario will still spend millions on Hep C victims
Government Commends Federal Hepatitis C Funding
Treatment for Hepatitis C Less Than Half as Likely if You Have No Insurance
Hepatitis C virus enzyme sites revealed
AVI BioPharma Announces Hepatitis C Virus Clinical Study Modification
Low CD4 cell count and hepatitis C coinfection risk factors for acute
kidney failure in HIV-infected patients
Hepatitis C ad blitz raises ethical qualms
Hepatitis C testing urged
Cholesterol drugs may treat hepatitis C - study
Sexual dysfunction common for men with hepatitis C
85% of rural Chinese HIV-positives also have hepatitis C
Jury indicts hepatitis C inmate for assault after spitting on guards
Innogenetics reports preclinical data on prophylactic hepatitis C
vaccine and identification of neutralizing HCV antibodies with unique features
Treating hepatitis C recurrence after liver transplantation“A new study on recurring hepatitis C in patients who underwent a liver transplant found that better results were achieved when using a combination of pegylated interferon (a longer-acting form of the drug) and the antiviral drug ribavirin than standard interferon and ribavirin. In addition, failure to respond to the therapy early on was useful in predicting whether it would ultimately succeed.”
Clinical Trials, Cohort Studies, and Pilot Studies
effects and predictors of a 24-week course of interferon alpha-2b plus
ribavirin combination therapy for patients with chronic hepatitis C.
M, et al. J
Gastroenterol Hepatol. 2006 Jul;21(7):1177-1183.
Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: The effect of pegylated interferon plus ribavirin treatment. Elefsiniotis IS, et al. World J Gastroenterol. 2006 Jul 21;12(27):4420-4.
Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response. Trapero-Marugan M, et al. Aliment Pharmacol Ther. 2006 Jul 1;24(1):117-28.
of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a
(40 kDa) and ribavirin.
immune activation as a risk factor for the onset of depression during interferon-alpha
alpha 2a treatment for chronic hepatitis C in patients on chronic
pilot study of hepatitis C virus prevalence in liver transplant surgeons.
benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled
trial and economic evaluation.
Basic and Applied Science, Pre-Clinical Studies
HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. Ghaziani T, et al. J Hepatol. 2006 Jul;45(1):5-12. Epub 2006 Feb 3
Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Folgori A, et al. Gut. 2006 Jul;55(7):1012-9. Epub 2006 Feb 16.
Induction of antigen-specific immune responses in vivo after vaccination with dendritic cells transduced with adenoviral vectors encoding hepatitis C virus NS3. Xiang M, et al. Viral Immunol. 2006 Summer;19(2):210-9.
and therapeutic implications of hepatitis C virus compartmentalization.
liver sinusoidal endothelial cells induce apoptosis in activated T cells: a
role in tolerance induction.
Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse
Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. Smyk-Pearson S, et al. J Infect Dis. 2006 Aug 15;194(4):454-63. Epub 2006 Jul 12.
Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy. Bower WA, et al. J Acquir Immune Defic Syndr. 2006 Jul;42(3):293-7.
Pegylated interferon alpha-2b plus ribavirin
for the treatment of chronic hepatitis C in HIV-coinfected patients.
GB Virus C (GBV-C) Infection in Hepatitis C Virus (HCV)/HIV-Coinfected
Patients Receiving HCV Treatment: Importance of the GBV-C Genotype.
of and risk factors for severe hepatotoxicity of nelfinavir-containing
regimens among HIV-infected patients with chronic hepatitis C.
Complementary and Alternative Therapies
Assessment of liver fibrosis by a noninvasive method of transient elastography
and biochemical markers.
The Case of Scott Ortiz: A clash between criminal justice and public health. Venters HD, et al. Harm Reduct J. 2006 Jul 24;3(1):21 [Epub ahead of print].
The Impact of Chronic Hepatitis C and Comorbid Psychiatric Illnesses on Health-related
Quality of Life.
Patients' experiences related to anti-viral treatment for hepatitis C. Fraenkel L, et al. Patient Educ Couns. 2006 Jul;62(1):148-55. Epub 2005 Aug 10.
Lifestyle changes and beliefs regarding disease severity in patients with chronic hepatitis C. Castera L, et al. J Viral Hepat. 2006 Jul;13(7):482-8.
C is the most common, chronic blood-borne